Market Herald logo

Subscribe

Be the first with the news that moves the market
  • The Gummy Project (GUMY) receives its first repeat order from its existing customer Bard on The Beach
  • Bard on the Beach was established in 1990 with a mandate to provide Vancouver residents and tourists with affordable, accessible Shakespearean productions
  • The Gummy Project (GUMY) sells low sugar, plant based gummy products while raising money (and awareness) to support endangered keystone species
  • The Gummy Project (GUMY) is unchanged today currently trading at C$0.01 as of Jul 26, 1:12 p.m. EDT

The Gummy Project (GUMY) has received its first repeat order from existing customer Bard on The Beach.

Charlie Lamb, President and CEO of Gummy, commented on the news.

“We’re thrilled to receive our first repeat order for our Watermelon Sharks and Peachy Bees from the local community jewel that is Bard. We view this as an indication that the local community strongly embraces our mandate to support endangered keystone species and very much enjoys our delicious gummies.”

Bard on the Beach was established in 1990 with a mandate to provide Vancouver residents and tourists with affordable, accessible Shakespearean productions.

Bard is now a professional company engaging hundreds of talented artists, artisans, technicians and year-round administrators. Bard’s primary focus is its annual festival in Vanier Park/Sen̓ákw, which annually attracts over 100,000 people. Bard’s other key elements include education and training initiatives for artistic and general communities.

Max Forsyth, Operations Manager of Bard, added,

“Bard on the Beach is thrilled to be furthering this partnership. Our patrons are overjoyed that they can snack on a delicious vegan and gluten free treat all summer long.”

The Gummy Project (GUMY) sell low sugar, plant based gummy products while raising money (and awareness) to support endangered keystone species.

The Gummy Project (GUMY) is unchanged today currently trading at C$0.01 as of Jul 26, 1:12 p.m. EDT.


.

More From The Market Herald

" Update from Revive Therapeutics (CSE:RVV) on Phase 3 clinical trial for Bucillamine in COVID-19

Revive Therapeutics (RVV) has provided an update on the company’s U.S. Food & Drug Administration (FDA) Phase 3 clinical trial.

" EnWave (TSXV:ENW) signs technology evaluation agreement with Canadian cannabis cultivator

EnWave Corporation (ENW) has signed an agreement with a Canadian cannabis company to use its 10kW Radiant Energy Vacuum (REV) technology.

" Core One Labs (CSE:COOL) subsidiary Vocan successfully converts Psilocin precursor into Psilocybin

Core One Labs (CSE:COOL) subsidiary Vocan Biotechnologies has converted psilocin developed by Awakened Biosciences into viable API psilocybin.